C
Chrystele Locher
Publications - 25
Citations - 1143
Chrystele Locher is an academic researcher. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 8, co-authored 19 publications receiving 877 citations.
Papers
More filters
Journal ArticleDOI
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman,Gérard Zalcman,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Olivier Molinier,Romain Corre,Isabelle Monnet,Valérie Gounant,Frédéric Rivière,H. Janicot,Radj Gervais,Chrystele Locher,Bernard Milleron,Quan Tran,Marie-Paule Lebitasy,Franck Morin,Christian Creveuil,Jean-Jacques Parienti,Arnaud Scherpereel +21 more
TL;DR: Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.
Journal ArticleDOI
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).
Christos Chouaid,Cécile Dujon,Pascal Do,Isabelle Monnet,A. Madroszyk,Hervé Le Caer,Jean Bernard Auliac,Henri Berard,Pascal Thomas,Hervé Lena,Gilles Robinet,N. Baize,Acya Bizieux-Thaminy,G. Fraboulet,Chrystele Locher,Jacques Le Treut,S. Hominal,Alain Vergnenegre +17 more
TL;DR: Re-biopsy of advanced NSCLC is feasible in the real-world setting, with acceptable adverse events, and guidelines are needed on the indications of re-biops, the choice of procedure, the sampling site, and laboratory analysis.
Journal ArticleDOI
Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies
Chrystele Locher,Didier Debieuvre,D. Coëtmeur,François Goupil,Olivier Molinier,Thierry Collon,Charles Dayen,Jacques Le Treut,Bernard Asselain,Francis Martin,François Blanchon,Michel Grivaux +11 more
TL;DR: In ten years, lung cancer characteristics have changed: more women, more never-smokers, and more adenocarcinomas; the particular high increase in adenOCarcinoma rate deserves further analysis.
Journal ArticleDOI
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.
Gérard Zalcman,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Oliver Molinier,Romain Corre,Isabelle Monnet,Valérie Gounant,H. Janicot,Radj Gervais,Chrystele Locher,Bernard Milleron,Quan Tran,Marie Paule Lebitasy,Franck Morin,Christian Creveuil,Jean-Jacques Parienti,Arnaud Scherpereel,French Cooperative Thoracic Intergroup +20 more
TL;DR: This French multicenter randomized phase 3 trial randomized patients with unresectable, histologically proved MPM, age < 76, no prior chemo, PS 0-2, no thrombosis, nor bleeding to show a significant OS improvement, with 80% statistical power, 5% a-risk.
Journal ArticleDOI
[Ten-year evolution in non-small-cell lung cancer according to sex. Results of the KBP-2010-CPHG study by the College of General Hospital Respiratory Physicians].
Didier Debieuvre,Chrystele Locher,A.-C. Neidhardt,François Goupil,B. Lemaire,A.-S. Blanchet-Legens,D. Renault,J.-Y. Tavernier,P. Tagu,H. Mahmoud,M. Figueredo,Michel Grivaux +11 more
TL;DR: Le pourcentage de femmes avec un CBNPC a augmente en 10 ans, mais s’attenuent avec l’augmentation du pourcentages de non-fumeurs et d’adenocarcinomes chez l”homme.